Volume 30, Number 7—July 2024
Research Letter
Large-Scale Outbreak of Mycoplasma pneumoniae Infection, Marseille, France, 2023–2024
Abstract
We report a large-scale outbreak of Mycoplasma pneumoniae respiratory infections encompassing 218 cases (0.8% of 26,449 patients tested) during 2023–2024 in Marseille, France. The bacterium is currently circulating and primarily affects children <15 years of age. High prevalence of co-infections warrants the use of a syndromic diagnostic strategy.
Mycoplasma pneumoniae is known to cause upper respiratory tract infections and pneumonia, especially in children 5–15 years of age (1). Although mostly sporadic, M. pneumoniae infections may occur as successive epidemics every few years (1). The precedent outbreak was observed during the 2019–2020 cold season, simultaneously in several countries, just before onset the COVID-19 pandemic (2). Then, the number of cases observed worldwide decreased markedly during this pandemic. However, although the resurgence of most respiratory pathogens was gradually observed from 2021, incidence of M. pneumoniae remained particularly low until June 2023, when a major resurgence of cases was reported worldwide (2–3).
We describe M. pneumoniae respiratory infections diagnosed in Marseille, France, university hospitals during January 1, 2014–February 15, 2024. We analyzed retrospectively all respiratory samples tested with 1 of the following specific quantitative PCRs (qPCRs) for M. pneumoniae: qPCR carried out by point-of-care laboratories using the Biofire FilmArray Respiratory Panel 2 Plus Assay (bioMérieux, https://www.biomerieux.com); qPCR performed routinely at the core laboratory using the FTD Respiratory Pathogens 21 Assay (Siemens Healthineers, https://www.siemens-healthineers.com); or an in-house specific qPCR (4). We used OpenEpi version 3.01 (https://www.openepi.com) for statistical analyses and considered differences significant at p<0.05.
Overall, 98,401 samples from 74,355 patients were tested for M. pneumoniae as part of the diagnosis of respiratory infections during 2014–2024. Median patient age was 30 years (range 0–108 years); 52% were male and 48% female. M. pneumoniae was detected in 449 patients (0.6%). Median age of positive patients was 10 years (range 0–101 years); 57% were male and 43% female.
We observed a few M. pneumoniae outbreaks in Marseille during 2014–2020, with a peak in early 2020 (Figure). Incidence then declined until a resurgence was observed beginning in 2023. Initially, 9 cases were observed in January 2023, followed by 6 cases during February–May. Then, a major increase in diagnoses was observed during June 1, 2023–February 15, 2024 (203 total with a peak of 48 cases in December 2023). From January 2023 through mid-February 2024, we diagnosed 218 M. pneumoniae infections (0.8% of 26,449 patients tested), compared with 231 cases (0.3% of 71,952 patients tested) during January 2014–December 2022 (p<0.0001). Median age was significantly lower for patients diagnosed since 2023 than for previous years (8 vs. 15 years; p<0.0001) (Table). Concurrent presence of >1 respiratory viruses was found for 114/316 (36%) M. pneumoniae–positive patients. The prevalence of co-infections was significantly higher in children <5 years of age than in other age groups (p<0.0001). The most common co-infections were with rhinovirus (n = 49), influenza A virus (n = 13), respiratory syncytial virus (n = 12), human coronavirus OC43 (n = 10), influenza B virus (n = 9) and metapneumovirus (n = 9) (Appendix Figure 1). Co-infections were significantly less frequent in patients diagnosed during 2014–2022 (45/164 [27%]) compared with those diagnosed since 2023 (69/152 [45.4%]; p = 0.0008).
The increase of M. pneumoniae infection cases observed in our center are in line with observations from surveillance networks in France and throughout Europe (i.e., detection of the first epidemic sign in June 2023 until a peak reaching in December 2023) (2). High percentages of positivity (up to 50%) have been reported in China (5). In Marseille, we observed a lower percentage (1.8%), similar to the 0.89% observed in the United States since September 2023 (6). Most previous studies reported an increased incidence of M. pneumoniae infection particularly in school-age children and young adults (3,7). In Marseille, children <15 years were more affected during 2023–2024 than in previous seasons. However, we observed a switch regarding the population affected by the epidemic; adults became more affected beginning in January 2024 (Appendix Figure 2), possibly because of a massive transmission of the bacterium from infected children. We also observed a high rate of co-infections (≈50%), compared with 18% in the Netherlands (3). A high rate of co-infection with M. pneumoniae and other pathogens has also been previously reported in 65% of children and 34% of adults with acute respiratory infections in the United States (8). M. pneumoniae carriage ranging from 21% to 56% has also been reported in asymptomatic children (9). Interactions during co-detected microorganisms are complex, making it difficult to clearly define the contribution of each to respiratory infection. A high rate of asymptomatic carriers suggests a critical role for the nasopharyngeal microbiota in the clinical expression of respiratory infection.
There are several hypotheses for this re-emergence of M. pneumoniae, including the emergence of a new strain or a decline in individual and collective immunity. The current outbreak could be the usual periodic recurrence marked by an exacerbation resulting from a period of low exposure linked to restrictive measures during the COVID-19 pandemic. We did not investigate macrolide resistance, but reported resistance is low in Europe (10), and most studies described favorable outcomes after macrolide treatment (7). The number of M. pneumoniae infection cases is probably underestimated, particularly because patients with mild symptoms are not systematically tested. The high prevalence of co-infections with respiratory viruses justifies the use of a syndromic diagnostic strategy.
Dr. Edouard is a medical bacteriologist at the Microbiological Laboratory at IHU–Méditerranée Infection in Marseille, France. Her research interests focus on infectious diseases and microbiology including intracellular bacteria and emerging pathogens.
Acknowledgments
We thank Didier Stoupan for his technical support.
Data are available from the corresponding author upon reasonable request.
References
- Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17:697–728. DOIPubMedGoogle Scholar
- Meyer Sauteur PM, Beeton ML, Pereyre S, Bébéar C, Gardette M, Hénin N, et al.; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. Lancet Microbe. 2024;5:e100–1. DOIPubMedGoogle Scholar
- Nordholm AC, Søborg B, Jokelainen P, Lauenborg Møller K, Flink Sørensen L, Grove Krause T, et al. Mycoplasma pneumoniae epidemic in Denmark, October to December, 2023. Euro Surveill. 2024;29:
2300707 . DOIPubMedGoogle Scholar - Morel AS, Dubourg G, Prudent E, Edouard S, Gouriet F, Casalta JP, et al. Complementarity between targeted real-time specific PCR and conventional broad-range 16S rDNA PCR in the syndrome-driven diagnosis of infectious diseases. Eur J Clin Microbiol Infect Dis. 2015;34:561–70. DOIPubMedGoogle Scholar
- Li H, Li S, Yang H, Chen Z, Zhou Z. Resurgence of Mycoplasma pneumoniae by macrolide-resistant epidemic clones in China. Lancet Microbe. 2024:S2666-5247(23)00405-6.
- Edens C, Clopper BR, DeVies J, Benitez A, McKeever ER, Johns D, et al. Notes from the field: reemergence of Mycoplasma pneumoniae infections in children and adolescents after the COVID-19 pandemic, United States, 2018–2024. MMWR Morb Mortal Wkly Rep. 2024;73:149–51. DOIPubMedGoogle Scholar
- Zayet S, Poloni S, Plantin J, Hamani A, Meckert Y, Lavoignet CE, et al. Outbreak of Mycoplasma pneumoniae pneumonia in hospitalized patients: Who is concerned? Nord Franche-Comté Hospital, France, 2023-2024. Epidemiol Infect. 2024;152:
e46 . DOIPubMedGoogle Scholar - Diaz MH, Cross KE, Benitez AJ, Hicks LA, Kutty P, Bramley AM, et al. Identification of bacterial and viral codetections with Mycoplasma pneumoniae using the TaqMan array card in patients hospitalized with community-acquired pneumonia. Open Forum Infect Dis. 2016;3:
ofw071 . DOIPubMedGoogle Scholar - Koenen MH, de Groot RCA, de Steenhuijsen Piters WAA, Chu MLJN, Arp K, Hasrat R, et al. Mycoplasma pneumoniae carriage in children with recurrent respiratory tract infections is associated with a less diverse and altered microbiota. EBioMedicine. 2023;98:
104868 . DOIPubMedGoogle Scholar - Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:
e2220949 . DOIPubMedGoogle Scholar
Figure
Table
Cite This ArticleOriginal Publication Date: May 30, 2024
Table of Contents – Volume 30, Number 7—July 2024
EID Search Options |
---|
|
|
|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Florence Fenollar, IHU–Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France
Top